Marte Austreim
Research Subjects
Marte Austreim has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Caroline Hartwell Garred
Department of Cardiology, Herlev and Gentofte University Hospital , Borgmester Ib Juuls Vej 1, 2730 Herlev
5 shared publications - Lars Køber
Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
5 shared publications - Morten Schou
Department of Clinical Medicine, University of Copenhagen , Copenhagen
5 shared publications - Nina Nouhravesh
Department of Oncology, Rigshospitalet, Copenhagen University Hospital , Copenhagen
5 shared publications - Daniel Mølager Christensen
Department of Cardiology Copenhagen University Hospital—Herlev and Gentofte Copenhagen Denmark
4 shared publications - Emil Loldrup Fosbøl
Department of Cardiology, Rigshospitalet, Copenhagen University Hospital , Blegdamsvej 9, Copenhagen 2100
4 shared publications
Latest Publications
- Open Access
- 21 April 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (8) , e044072
Care and Outcomes of New‐Onset Heart Failure Across Vulnerable Populations: Temporal Trends in Mortality and Treatment in a Danish Nationwide Cohort From 2003 to 2022
Background: Heart failure (HF) prevalence is increasing. In a nationwide cohort study, we investigated temporal trends in care and outcomes of patients with new‐onset HF within vulnerable populations. Methods: There were 154 819 patients with new‐onset HF between 2003 and 2022 identified and included using Danish nationwide registries. Eight potentially vulnerable subgroups were defined (aged ≥80 years, women, low income, living alone, mental illness, non‐Western background, frail, and rural residency) and compared with their counterparts. Temporal trends in initiation of guideline‐recommended HF therapy and risk of all‐cause mortality were analyzed. Results: Initiation of guideline‐recommended HF therapies (mineralocorticoid‐receptor‐antagonists, β‐blockers, renin‐angiotensin system inhibitors) was generally successful, but initiation of mineralocorticoid receptor antagonists was insufficient in vulnerable patients. Five‐year all‐cause mortality decreased from 2003 to 2007 to 2018 to 2022; however, those aged ≥80 years, frail, and living alone experienced a smaller decrease (aged ≥80 years versus counterpart: adjusted hazard ratio [aHR], 0.74 [95% CI, 0.72–0.76] versus aHR, 0.63 [95% CI, 0.61–0.65]; frail versus counterpart: aHR, 0.74 [95% CI, 0.71–0.77] versus aHR, 0.67 [95% CI, 0.65–0.68]; living alone versus counterpart: aHR, 0.75 [95% CI, 0.73–0.77] versus aHR, 0.62 [95% CI, 0.60–0.64]); and patients with mental illness experienced no improvements (mental illness versus counterpart: aHR, 0.99 [95% CI, 0.87–1.12] versus aHR, 0.68 [95% CI, 0.67–0.70]). Six vulnerable groups had higher aHRs compared with their counterparts in 2018 to 2022. Conclusions: Initiation of guideline‐recommended therapies improved over the past 2 decades, but initiation of mineralocorticoid receptor antagonists was inadequate in vulnerable patients. Furthermore, the overall mortality risk declined, but 4 out of the 8 vulnerable groups experienced a lesser decline than their counterparts. Despite improvements, 6 vulnerable groups still had worse outcomes than their counterparts at the end of the study period. Our findings highlight the urgent need for more effort aimed at helping vulnerable subgroups of patients with HF.
- 21 April 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (8) , e044072
Open AccessCare and Outcomes of New‐Onset Heart Failure Across Vulnerable Populations: Temporal Trends in Mortality and Treatment in a Danish Nationwide Cohort From 2003 to 2022
Background: Heart failure (HF) prevalence is increasing. In a nationwide cohort study, we investigated temporal trends in care and outcomes of patients with new‐onset HF within vulnerable populations. Methods: There were 154 819 patients with new‐onset HF between 2003 and 2022 identified and included using Danish nationwide registries. Eight potentially vulnerable subgroups were defined (aged ≥80 years, women, low income, living alone, mental illness, non‐Western background, frail, and rural residency) and compared with their counterparts. Temporal trends in initiation of guideline‐recommended HF therapy and risk of all‐cause mortality were analyzed. Results: Initiation of guideline‐recommended HF therapies (mineralocorticoid‐receptor‐antagonists, β‐blockers, renin‐angiotensin system inhibitors) was generally successful, but initiation of mineralocorticoid receptor antagonists was insufficient in vulnerable patients. Five‐year all‐cause mortality decreased from 2003 to 2007 to 2018 to 2022; however, those aged ≥80 years, frail, and living alone experienced a smaller decrease (aged ≥80 years versus counterpart: adjusted hazard ratio [aHR], 0.74 [95% CI, 0.72–0.76] versus aHR, 0.63 [95% CI, 0.61–0.65]; frail versus counterpart: aHR, 0.74 [95% CI, 0.71–0.77] versus aHR, 0.67 [95% CI, 0.65–0.68]; living alone versus counterpart: aHR, 0.75 [95% CI, 0.73–0.77] versus aHR, 0.62 [95% CI, 0.60–0.64]); and patients with mental illness experienced no improvements (mental illness versus counterpart: aHR, 0.99 [95% CI, 0.87–1.12] versus aHR, 0.68 [95% CI, 0.67–0.70]). Six vulnerable groups had higher aHRs compared with their counterparts in 2018 to 2022. Conclusions: Initiation of guideline‐recommended therapies improved over the past 2 decades, but initiation of mineralocorticoid receptor antagonists was inadequate in vulnerable patients. Furthermore, the overall mortality risk declined, but 4 out of the 8 vulnerable groups experienced a lesser decline than their counterparts. Despite improvements, 6 vulnerable groups still had worse outcomes than their counterparts at the end of the study period. Our findings highlight the urgent need for more effort aimed at helping vulnerable subgroups of patients with HF.
- 18 November 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (27) , 3625-3635
Temporal trends in the use of oral anticoagulants and clinical outcomes in older, elderly, and very elderly patients with atrial fibrillation: a Danish nationwide study
Background and Aims: Anticoagulation therapy in patients with atrial fibrillation (AF) has changed over time, particularly following the introduction of direct oral anticoagulants. However, it is unknown how the uptake of anticoagulation therapy and the related clinical outcomes in elderly patients with AF have changed over time. Methods: Patients with new-onset AF were included and divided into three age groups: older adults (65–74 years), elderly (75–84 years), and very elderly (≥85 years). Temporal trends in the initiation of oral anticoagulants (OACs), the stroke-free survival, major bleedings including intracerebral haemorrhage (ICH), and all-cause mortality were investigated from 1999 to 2022. Results: In total, 243 938 patients were included, of whom 89 184 (36.6%) were older adults, 99 002 were elderly (40.6%), and 55 752 (22.8%) were very elderly. The proportion of very elderly patients with AF receiving OACs was 71% in 2022. The absolute improvement in the 5-year probability of stroke-free survival was 10.1% in the older adult patients, 12.8% in the elderly patients, and 3.5% in the very elderly patients. The 5-year absolute risk of ICH increased among the elderly and very elderly AF patients. Conclusions: Over the past two decades, the risk of stroke decreased significantly among all age groups, with no subsequent increase in the risk of bleeding among older adults in an era where OACs were almost fully implemented. In the very elderly patients aged ≥85 years, the risk of stroke only slightly improved over time, with an increase in the risk of ICH.
- 18 November 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (27) , 3625-3635
Temporal trends in the use of oral anticoagulants and clinical outcomes in older, elderly, and very elderly patients with atrial fibrillation: a Danish nationwide study
Background and Aims: Anticoagulation therapy in patients with atrial fibrillation (AF) has changed over time, particularly following the introduction of direct oral anticoagulants. However, it is unknown how the uptake of anticoagulation therapy and the related clinical outcomes in elderly patients with AF have changed over time. Methods: Patients with new-onset AF were included and divided into three age groups: older adults (65–74 years), elderly (75–84 years), and very elderly (≥85 years). Temporal trends in the initiation of oral anticoagulants (OACs), the stroke-free survival, major bleedings including intracerebral haemorrhage (ICH), and all-cause mortality were investigated from 1999 to 2022. Results: In total, 243 938 patients were included, of whom 89 184 (36.6%) were older adults, 99 002 were elderly (40.6%), and 55 752 (22.8%) were very elderly. The proportion of very elderly patients with AF receiving OACs was 71% in 2022. The absolute improvement in the 5-year probability of stroke-free survival was 10.1% in the older adult patients, 12.8% in the elderly patients, and 3.5% in the very elderly patients. The 5-year absolute risk of ICH increased among the elderly and very elderly AF patients. Conclusions: Over the past two decades, the risk of stroke decreased significantly among all age groups, with no subsequent increase in the risk of bleeding among older adults in an era where OACs were almost fully implemented. In the very elderly patients aged ≥85 years, the risk of stroke only slightly improved over time, with an increase in the risk of ICH.
- Open Access
- 13 September 2025
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 58
Care and outcomes of first-time myocardial infarction among vulnerable populations in Denmark, 2003–22: a nationwide registry-based cohort study
- 13 September 2025
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 58
Open AccessCare and outcomes of first-time myocardial infarction among vulnerable populations in Denmark, 2003–22: a nationwide registry-based cohort study
- Open Access
- 4 February 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (3) , e037973
Temporal Trends in Mortality and Hospitalization Risk in Patients With Heart Failure According to the Hospital Frailty Risk Score
Background: Heart failure (HF) and frailty often coexist. However, it is unknown how the interplay between HF and frailty at HF onset impacts prognosis of frail patients with HF and how this has evolved over time. Methods and Results: We identified 131 235 patients with new‐onset HF (median age 74 years, 39.7% women) from Danish nationwide registers in 1999 to 2017. Stratification according to the Hospital Frailty Risk Score resulted in (1) 102 635 (78%) nonfrail, (2) 26 054 (20%) moderately frail, and (3) 2609 (2%) severely frail patients. The proportion of moderately frail patients increased from 13.2% to 24.9%. Five‐year absolute risks of all‐cause mortality, HF hospitalization, and non‐HF hospitalization were calculated using the Kaplan‐Meier and Aalen‐Johansen estimators. From 1999 to 2002 to 2003 to 2017, all‐cause mortality risk (95% CI) declined from 56.4% (55.8%–57.0%) to 33.3% (32.6%–34.1%), 79.8% (78.5%–81.0%) to 58.6% (57.2%–60.1%), and 90.8% (85.6%–96.0%) to 79.8% (76.4%–83.2%) in nonfrail, moderately frail, and severely frail patients, respectively. HF hospitalization risk remained almost constant over the study period. Non‐HF hospitalization risk declined from 74.0% (73.5%–74.5%) to 65.8% (65.0%–66.5%) in nonfrail patients and remained stable overall in moderately frail and severely frail patients over the study period. Conclusions: We observed an increase in frail patients. Mortality decreased for all frailty groups but remained high for severely frail patients. These findings indicate the need for further evidence on the optimization of care for frail patients with HF, and future research should address the development of comprehensive management strategies, integrating frailty assessment into standard clinical care and focused care for older patients with HF.
- 4 February 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (3) , e037973
Open AccessTemporal Trends in Mortality and Hospitalization Risk in Patients With Heart Failure According to the Hospital Frailty Risk Score
Background: Heart failure (HF) and frailty often coexist. However, it is unknown how the interplay between HF and frailty at HF onset impacts prognosis of frail patients with HF and how this has evolved over time. Methods and Results: We identified 131 235 patients with new‐onset HF (median age 74 years, 39.7% women) from Danish nationwide registers in 1999 to 2017. Stratification according to the Hospital Frailty Risk Score resulted in (1) 102 635 (78%) nonfrail, (2) 26 054 (20%) moderately frail, and (3) 2609 (2%) severely frail patients. The proportion of moderately frail patients increased from 13.2% to 24.9%. Five‐year absolute risks of all‐cause mortality, HF hospitalization, and non‐HF hospitalization were calculated using the Kaplan‐Meier and Aalen‐Johansen estimators. From 1999 to 2002 to 2003 to 2017, all‐cause mortality risk (95% CI) declined from 56.4% (55.8%–57.0%) to 33.3% (32.6%–34.1%), 79.8% (78.5%–81.0%) to 58.6% (57.2%–60.1%), and 90.8% (85.6%–96.0%) to 79.8% (76.4%–83.2%) in nonfrail, moderately frail, and severely frail patients, respectively. HF hospitalization risk remained almost constant over the study period. Non‐HF hospitalization risk declined from 74.0% (73.5%–74.5%) to 65.8% (65.0%–66.5%) in nonfrail patients and remained stable overall in moderately frail and severely frail patients over the study period. Conclusions: We observed an increase in frail patients. Mortality decreased for all frailty groups but remained high for severely frail patients. These findings indicate the need for further evidence on the optimization of care for frail patients with HF, and future research should address the development of comprehensive management strategies, integrating frailty assessment into standard clinical care and focused care for older patients with HF.
- Open Access
- 22 July 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
Temporal trends in mortality, heart failure hospitalization, and stroke in heart failure patients with and without atrial fibrillation: a nationwide study from 1997 to 2018 on 152 059 patients
Aims: We aimed to investigate temporal trends in all-cause mortality, heart failure (HF) hospitalization, and stroke from 1997 to 2018 in patients diagnosed with both HF and atrial fibrillation (AF). Methods and results: From Danish nationwide registers, we identified 152 059 patients with new-onset HF between 1997 and 2018. Patients were grouped according to year of new-onset HF and AF-status: Prevalent AF (n = 34 734), New-onset AF (n = 12 691), and No AF (n = 104 634). Median age decreased from 76 to 73 years between 1997 and 2018. The proportion of patients with prevalent or new-onset AF increased from 24.7% (n = 9256) to 35.8% (n = 14 970). Five-year risk of all-cause mortality went from 69.1% [confidence interval (CI): 67.9–70.2%] to 51.3% (CI: 49.9–52.7%), 62.3% (CI: 60.5–64.4%) to 43.0% (CI: 40.5–45.5%), and 61.9% (CI: 61.3–62.4%) to 36.7% (CI: 35.9–37.6%) for the Prevalent AF, New-onset AF, and No AF-group, respectively. Minimal changes were observed in the risk of HF-hospitalization. Five-year stroke risk decreased from 8.5% (CI: 7.8–9.1%) to 5.0% (CI: 4.4–5.5%) for the prevalent AF group, 8.2% (CI: 7.2–9.2%) to 4.6% (CI: 3.7–5.5%) for new-onset AF, and 6.3% (CI: 6.1–6.6%) to 4.9% (CI: 4.6–5.3%) for the No AF group. Simultaneously, anticoagulant therapy increased for patients with prevalent (from 42.7 to 93.1%) and new-onset AF (from 41.9 to 92.5%). Conclusion: From 1997 to 2018, we observed an increase in patients with HF and co-existing AF. Mortality decreased for all patients, regardless of AF-status. Anticoagulation therapy increased, and stroke risk for patients with AF was reduced to a similar level as patients without AF in 2013–2018.
- 22 July 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
Open AccessTemporal trends in mortality, heart failure hospitalization, and stroke in heart failure patients with and without atrial fibrillation: a nationwide study from 1997 to 2018 on 152 059 patients
Aims: We aimed to investigate temporal trends in all-cause mortality, heart failure (HF) hospitalization, and stroke from 1997 to 2018 in patients diagnosed with both HF and atrial fibrillation (AF). Methods and results: From Danish nationwide registers, we identified 152 059 patients with new-onset HF between 1997 and 2018. Patients were grouped according to year of new-onset HF and AF-status: Prevalent AF (n = 34 734), New-onset AF (n = 12 691), and No AF (n = 104 634). Median age decreased from 76 to 73 years between 1997 and 2018. The proportion of patients with prevalent or new-onset AF increased from 24.7% (n = 9256) to 35.8% (n = 14 970). Five-year risk of all-cause mortality went from 69.1% [confidence interval (CI): 67.9–70.2%] to 51.3% (CI: 49.9–52.7%), 62.3% (CI: 60.5–64.4%) to 43.0% (CI: 40.5–45.5%), and 61.9% (CI: 61.3–62.4%) to 36.7% (CI: 35.9–37.6%) for the Prevalent AF, New-onset AF, and No AF-group, respectively. Minimal changes were observed in the risk of HF-hospitalization. Five-year stroke risk decreased from 8.5% (CI: 7.8–9.1%) to 5.0% (CI: 4.4–5.5%) for the prevalent AF group, 8.2% (CI: 7.2–9.2%) to 4.6% (CI: 3.7–5.5%) for new-onset AF, and 6.3% (CI: 6.1–6.6%) to 4.9% (CI: 4.6–5.3%) for the No AF group. Simultaneously, anticoagulant therapy increased for patients with prevalent (from 42.7 to 93.1%) and new-onset AF (from 41.9 to 92.5%). Conclusion: From 1997 to 2018, we observed an increase in patients with HF and co-existing AF. Mortality decreased for all patients, regardless of AF-status. Anticoagulation therapy increased, and stroke risk for patients with AF was reduced to a similar level as patients without AF in 2013–2018.
- Open Access
Temporal trends in mortality, heart failure hospitalization, and stroke in heart failure patients with and without atrial fibrillation: A nationwide study from 1997-2018 on 152,059 patients
Background: Given the many advances in treating heart failure (HF) and atrial fibrillation (AF) separately over the past decades, it remains unclear how the prognosis of patients diagnosed with both conditions has changed over time. We aimed to investigate the temporal trends in clinical outcomes from 1997 to 2018 in patients diagnosed with both HF and AF. Methods: From Danish nationwide registries, we identified 152,059 patients with a first-time HF-diagnosis from 1997 to 2018. Patients were grouped according to year of new-onset HF and AF-status: Prevalent AF (n=34,734), New-onset HF (n=12,691), and No AF (n=104,634). Outcomes of interest were the five-year risk of all-cause mortality, HF-hospitalization, and stroke. Results: Between 1997 and 2018, the proportion of patients with prevalent or new-onset AF increased from 24.7% (n=9256) to 35.8% (n=14,970). The five-year risk of all-cause mortality decreased from 69.1% (95% CI): 67.9%-70.2%) to 51.3% (49.9%-52.7%), 62.3% (60.5%-64.4%) to 43.0% (40.5%-45.5%), and 61.9% (61.3%-62.4%) to 36.7% (35.9%-37.6%) for the prevalent AF, new-onset AF, and no AF group, respectively. Minimal changes were observed in the risk of HF-hospitalization. The five-year risk of stroke decreased from 8.5% (7.8%-9.1%) to 5.0% (4.4%-5.5%) in the prevalent AF group, 8.2% (7.2%-9.2%) to 4.6% (3.7%-5.5%) in the new-onset AF group, and 6.3% (6.1%-6.6%) to 4.9% (4.6%-5.3%) in the no AF group. Simultaneously, patients prescribed anticoagulant therapy within 90 days after HF-onset increased from 42.7% to 93.1% in patients with prevalent AF and 41.9% to 92.5% in patients with new-onset AF. Conclusion: From 1997 to 2018, we observed an increase in patients with HF and coexisting AF. Mortality and stroke risk decreased across all patient groups regardless of AF-status. Anticoagulation therapy increased, and stroke risk in patients with HF and AF was reduced to similar levels as HF patients without AF at the end of the study period. Clinical Perspective: What is new?: In patients with heart failure, an increasing proportion had concomitant atrial fibrillation in 2018 versus 1997. The mortality- and stroke risk decreased for all patients with heart failure over the past two decades, also for patients with coexisting atrial fibrillation, and more patients received guideline-recommended therapy in 2018 versus in 1997. What are the clinical implications?: The increasing trend of patients with heart failure and coexisting atrial fibrillation necessitates a better understanding of the coexistence of these two conditions, of which this study provides insight into the evolving prognosis and management landscape of individuals with both heart failure and atrial fibrillation over the past two decades. Graphical
Open AccessTemporal trends in mortality, heart failure hospitalization, and stroke in heart failure patients with and without atrial fibrillation: A nationwide study from 1997-2018 on 152,059 patients
Background: Given the many advances in treating heart failure (HF) and atrial fibrillation (AF) separately over the past decades, it remains unclear how the prognosis of patients diagnosed with both conditions has changed over time. We aimed to investigate the temporal trends in clinical outcomes from 1997 to 2018 in patients diagnosed with both HF and AF. Methods: From Danish nationwide registries, we identified 152,059 patients with a first-time HF-diagnosis from 1997 to 2018. Patients were grouped according to year of new-onset HF and AF-status: Prevalent AF (n=34,734), New-onset HF (n=12,691), and No AF (n=104,634). Outcomes of interest were the five-year risk of all-cause mortality, HF-hospitalization, and stroke. Results: Between 1997 and 2018, the proportion of patients with prevalent or new-onset AF increased from 24.7% (n=9256) to 35.8% (n=14,970). The five-year risk of all-cause mortality decreased from 69.1% (95% CI): 67.9%-70.2%) to 51.3% (49.9%-52.7%), 62.3% (60.5%-64.4%) to 43.0% (40.5%-45.5%), and 61.9% (61.3%-62.4%) to 36.7% (35.9%-37.6%) for the prevalent AF, new-onset AF, and no AF group, respectively. Minimal changes were observed in the risk of HF-hospitalization. The five-year risk of stroke decreased from 8.5% (7.8%-9.1%) to 5.0% (4.4%-5.5%) in the prevalent AF group, 8.2% (7.2%-9.2%) to 4.6% (3.7%-5.5%) in the new-onset AF group, and 6.3% (6.1%-6.6%) to 4.9% (4.6%-5.3%) in the no AF group. Simultaneously, patients prescribed anticoagulant therapy within 90 days after HF-onset increased from 42.7% to 93.1% in patients with prevalent AF and 41.9% to 92.5% in patients with new-onset AF. Conclusion: From 1997 to 2018, we observed an increase in patients with HF and coexisting AF. Mortality and stroke risk decreased across all patient groups regardless of AF-status. Anticoagulation therapy increased, and stroke risk in patients with HF and AF was reduced to similar levels as HF patients without AF at the end of the study period. Clinical Perspective: What is new?: In patients with heart failure, an increasing proportion had concomitant atrial fibrillation in 2018 versus 1997. The mortality- and stroke risk decreased for all patients with heart failure over the past two decades, also for patients with coexisting atrial fibrillation, and more patients received guideline-recommended therapy in 2018 versus in 1997. What are the clinical implications?: The increasing trend of patients with heart failure and coexisting atrial fibrillation necessitates a better understanding of the coexistence of these two conditions, of which this study provides insight into the evolving prognosis and management landscape of individuals with both heart failure and atrial fibrillation over the past two decades. Graphical